Compare CENX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENX | ACAD |
|---|---|---|
| Founded | 1995 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.3B |
| IPO Year | 2004 | 2000 |
| Metric | CENX | ACAD |
|---|---|---|
| Price | $46.22 | $24.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $65.67 | $30.55 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 3.23 | 0.02 |
| Revenue | ★ $1,893,200,000.00 | $726,437,000.00 |
| Revenue This Year | $20.77 | $18.80 |
| Revenue Next Year | $14.58 | $11.70 |
| P/E Ratio | ★ $14.35 | $1,241.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $20.21 | $19.69 |
| 52 Week High | $70.43 | $28.35 |
| Indicator | CENX | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 51.72 |
| Support Level | $43.38 | $20.56 |
| Resistance Level | $47.35 | $25.36 |
| Average True Range (ATR) | 1.93 | 0.76 |
| MACD | 0.81 | -0.26 |
| Stochastic Oscillator | 85.76 | 23.84 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. The company also owns a carbon anode production facility in the Netherlands.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.